Icosapent Ethyl Drug Reduces Risk of Recurrent Cardiovascular Events

Further insights from the REDUCE-IT trial show that high-dose, pure and stable EPA omega 3 drug not only reduces the burden of first cardiovascular events but also subsequent and total heart attacks, strokes, and other measures
Source: BWH News - Category: Hospital Management Source Type: news